US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Gene Editing

417.37

+7.231.76%

Number of Gainers:5

Number of Losers:- -

Number of Flat:- -

PE:- -

High:425.58

Open:410.64

Low:410.45

Close:410.14

Volume:12.96M

Turnover:146.05M

Market Cap:8.96B

Float Cap:8.31B

Loading ...

Hitachi Cooling & Heating Supports Hong Kong's Net-Zero Transition with BEAM Plus-Aligned VRF Solutions

Is CRISPR Therapeutics (CRSP) Attractive After Recent Share Price Weakness And DCF Upside?

Simply Wall St.

Sangamo Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview

Sangamo Therapeutics schedules fourth-quarter and full-year 2025 earnings call

Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), DocGo (DCGO) and Editas Medicine (EDIT)

Crispr Therapeutics Completes $600 Million Convertible Notes Offering

Analysts Are Bullish on These Healthcare Stocks: Beam Therapeutics (BEAM), Pelthos Therapeutics (PTHS)

CRISPR Therapeutics’ CASGEVY Progress Reframes Growth And Valuation Story

Simply Wall St.

Sangamo Therapeutics Inc expected to post a loss of 6 cents a share - Earnings Preview

Press Release: Morningstar, Inc. Declares Quarterly Dividend of 50 Cents Per Share

Cathie Wood Invests Over $10M in CRISPR and PAYP Stocks, Trims Stakes in TER and IONS

CRSP, SOLQ: Cathie Wood’s ARK ‘Buys the Dip’ in CRISPR and Solana Staking ETF

Crispr Therapeutics prices upsized convertible senior notes offering

Regulatory Disruptions at FDA Threaten Editas Medicine’s Gene-Editing Timelines and Commercial Prospects

Cathie Wood’s ARK Investment buys 281K shares of Crispr Therapeutics today

What's Going On With CRISPR Therapeutics Stock Today?

Benzinga_recent_news

Crispr Therapeutics falls -9.2%

Crispr Therapeutics Falls on $350M Senior Note Private Placement

CRISPR Therapeutics plans USD 350 million convertible senior notes offering due 2031

CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4556/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4556","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","market":"US","secType":"PLATE","nameCN":"Gene Editing","latestPrice":417.3733,"timestamp":1774295999999,"preClose":410.14468,"halted":0,"volume":12955202,"delay":0,"changeRate":0.017625,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":7.228607,"latestTime":"03-23 16:00:00 EDT","open":410.63986,"high":425.57993,"low":410.4473,"amount":146046037.042947,"amplitude":0.036896,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1774310400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":2.306903,"peRate":-6.637913,"turnoverRate":0.017365,"increases":5,"decrements":0,"flats":0,"marketCap":8961551184,"floatMarketCap":8313308016},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4556\",,,,,undefined,":{"symbol":"BK4556","high":425.57993,"amplitude":0.036896,"preClose":410.14468,"low":410.4473,"pbRate":"2.306903","latestPrice":417.3733,"volume":12955202,"delay":0,"open":410.63986,"prevYearClose":431.70972,"prevWeekClose":410.1447,"prevMonthClose":496.6623,"prevQuarterClose":431.7097,"fiveDayClose":428.3356,"twentyDayClose":463.0606,"sixtyDayClose":453.0773,"secType":"PLATE","market":"US","turnoverRate":0.017365,"peRate":-6.637913,"marketCap":8961551184,"floatMarketCap":8313308016,"timestamp":1774295999999,"nameCN":"Gene Editing"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4556\",,,,undefined,":{"bkCode":"BK4556","up":5,"down":0,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4556\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621077295","title":"Hitachi Cooling & Heating Supports Hong Kong's Net-Zero Transition with BEAM Plus-Aligned VRF Solutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2621077295","media":"prnewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621077295?lang=en_us&edition=fundamental","pubTime":"2026-03-23 18:25","pubTimestamp":1774261500,"startTime":"0","endTime":"0","summary":"HONG KONG, March 23, 2026 /PRNewswire/ -- As cities push toward net-zero emissions, Hong Kong is tightening building regulations and accelerating retrofits under the BEAM Plus framework. Higher expectations for energy performance and lower refrigerant GWP are reshaping HVAC standards. In a dense urban environment with limited plant rooms and constrained rooftops, conventional VRF systems often face installation challenges. Hitachi Cooling & Heating addresses these demands with VRF solutions designed for efficiency, flexibility, and alignment with BEAM Plus requirements.Complementing this highefficiency approach, air365 SideSmart, the world's first slim modular VRF, addresses Hong Kong's space constraints with an exclusive concept starting from just 1650×1050×420mm. A single 18HP module matches the capacity of conventional topdischarge units while occupying far less space. Its modular design allows up to four interconnected units, delivering a maximum of 72HP , along with flexible confi","market":"fut","thumbnail":"https://mma.prnewswire.com/media/2939848/Hitachi_air365_Max_Pro.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/2939848/Hitachi_air365_Max_Pro.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/hitachi-cooling--heating-supports-hong-kongs-net-zero-transition-with-beam-plus-aligned-vrf-solutions-302721936.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1861558580.USD","BK4535","BK4588","BK4139","BK4556","BEAM","LU1861559042.SGD","BK4611","BK4505","BK4585"],"gpt_icon":0},{"id":"2621193707","title":"Is CRISPR Therapeutics (CRSP) Attractive After Recent Share Price Weakness And DCF Upside?","url":"https://stock-news.laohu8.com/highlight/detail?id=2621193707","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621193707?lang=en_us&edition=fundamental","pubTime":"2026-03-22 14:08","pubTimestamp":1774159694,"startTime":"0","endTime":"0","summary":"Wondering whether CRISPR Therapeutics at around US$46.24 is offering good value, or if the recent excitement is already priced in? This breakdown is designed to help you frame that question clearly.\nThe stock is up 12.2% over the past year, even though it shows a 5.1% decline over 7 days, a 13.5% decline over 30 days, and a 14.0% decline year to date. Recent trading has therefore looked quite different to the longer term picture.\nRecent headlines around CRISPR Therapeutics have focused on...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/is-crispr-therapeutics-crsp-attractive-after-recent-share-pr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/is-crispr-therapeutics-crsp-attractive-after-recent-share-pr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4211","LU1861559042.SGD","CRSP","BK4611","BK4588","BK4556","BK4585","FCF","LU1861558580.USD","BK4139","DCF"],"gpt_icon":0},{"id":"2621751399","title":"Sangamo Therapeutics Inc  expected to post a loss of 6 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2621751399","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621751399?lang=en_us&edition=fundamental","pubTime":"2026-03-21 04:02","pubTimestamp":1774036940,"startTime":"0","endTime":"0","summary":"Sangamo Therapeutics Inc  expected to post a loss of6cents a share - Earnings Preview Sangamo Therapeutics Inc SGMO.OQ SGMO.O is expected to  show a rise in quarterly revenue when it reports  results ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N40828V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","BK4139","SGMO"],"gpt_icon":0},{"id":"2620276609","title":"Sangamo Therapeutics schedules fourth-quarter and full-year 2025 earnings call","url":"https://stock-news.laohu8.com/highlight/detail?id=2620276609","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620276609?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:03","pubTimestamp":1773950598,"startTime":"0","endTime":"0","summary":"Sangamo scheduled the release of its fourth quarter and full year 2025 financial results for March 30, 2026, after the market closes.A conference call is set for March 30, 2026 at 4:30 p.m. Eastern, with registration available at this link.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL3q5gHW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SG9999014005.SGD","LU2095319765.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4139","NDAQ","IE00BN0W2V16.EUR","BK4588","BK4556","SG9999014021.USD","SGMO","SG9999014013.SGD","IE00BN0W2T93.GBP","SG9999014039.USD","BK4585","LU0314104364.USD","LU2210149790.SGD","IE00BN0W2W23.USD","LU2210150020.SGD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2620842123","title":"Analysts Offer Insights on Healthcare Companies: Perspective Therapeutics (CATX), DocGo (DCGO) and Editas Medicine (EDIT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620842123","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620842123?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:50","pubTimestamp":1773748226,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Perspective Therapeutics (CATX – Research Report), DocGo (DCGO – ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-perspective-therapeutics-catx-docgo-dcgo-and-editas-medicine-edit-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-perspective-therapeutics-catx-docgo-dcgo-and-editas-medicine-edit-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4556","BK4581","DCGO","XBI","LU0029874061.USD","LABU","EDIT","CATX","HCSG","BK4196","BK4139","LU0128526141.USD","XLV","BK4137","BK4588","BK4585"],"gpt_icon":0},{"id":"2620491059","title":"Crispr Therapeutics Completes $600 Million Convertible Notes Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2620491059","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620491059?lang=en_us&edition=fundamental","pubTime":"2026-03-17 04:34","pubTimestamp":1773693281,"startTime":"0","endTime":"0","summary":"Crispr Therapeutics AG ( ($CRSP) ) just unveiled an announcement. On March 16, 2026, CRISPR Therapeutics AG completed a $600 million private offeri...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/crispr-therapeutics-completes-600-million-convertible-notes-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/crispr-therapeutics-completes-600-million-convertible-notes-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","CRSP","BK4556","BK4539","LU1861559042.SGD","BK4139","BK4007","BK4611","LENZ","BK4585","LU1861558580.USD"],"gpt_icon":0},{"id":"2619961469","title":"Analysts Are Bullish on These Healthcare Stocks: Beam Therapeutics (BEAM), Pelthos Therapeutics (PTHS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619961469","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619961469?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:50","pubTimestamp":1773669007,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Beam Therapeutics (BEAM – Research Report), Pelthos ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-beam-therapeutics-beam-pelthos-therapeutics-pths-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-beam-therapeutics-beam-pelthos-therapeutics-pths-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4535","BK4137","BK4139","BK4505","PTHS","BK4112","BK4611","BEAM","LABU","BLSG","LU1861558580.USD","BK4585","LU0029874061.USD","BLSX","LU1861559042.SGD","BK4556","BK4581","BK4588","XBI","LU0128526141.USD"],"gpt_icon":0},{"id":"2619912669","title":"CRISPR Therapeutics’ CASGEVY Progress Reframes Growth And Valuation Story","url":"https://stock-news.laohu8.com/highlight/detail?id=2619912669","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619912669?lang=en_us&edition=fundamental","pubTime":"2026-03-14 18:21","pubTimestamp":1773483682,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics (NasdaqGM:CRSP) reports strong commercial progress for its gene editing therapy CASGEVY, with higher than expected revenue contribution.\nThe company highlights a threefold increase in projected patient initiations for 2025, signaling growing real world adoption of CASGEVY.\nAlongside CASGEVY traction, CRISPR Therapeutics advances new gene editing programs and partnerships, expanding its clinical pipeline.\n\nCRISPR Therapeutics, trading at $48.75, is moving further into a...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-casgevy-progress-reframes-growth-and-val","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crsp/crispr-therapeutics/news/crispr-therapeutics-casgevy-progress-reframes-growth-and-val","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4611","LU1861558580.USD","LU2065732104.USD","CRSP","BK4556","PRGS","BK4588","BK4139","BK4585","LU1861559042.SGD","BK4097"],"gpt_icon":0},{"id":"2619148240","title":"Sangamo Therapeutics Inc  expected to post a loss of 6 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2619148240","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619148240?lang=en_us&edition=fundamental","pubTime":"2026-03-14 04:53","pubTimestamp":1773435186,"startTime":"0","endTime":"0","summary":"Sangamo Therapeutics Inc  expected to post a loss of6cents a share - Earnings Preview Sangamo Therapeutics Inc SGMO.OQ SGMO.O is expected to  show a rise in quarterly revenue when it reports  results ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260313:nL8N401234:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4556","SGMO","BK4139"],"gpt_icon":0},{"id":"2619110236","title":"Press Release: Morningstar, Inc. Declares Quarterly Dividend of 50 Cents Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2619110236","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619110236?lang=en_us&edition=fundamental","pubTime":"2026-03-14 04:15","pubTimestamp":1773432900,"startTime":"0","endTime":"0","summary":"The board of directors of Morningstar, Inc. , a leading provider of independent investment insights, today declared a quarterly dividend of 50 cents per share, consistent with the dividend paid in January. The dividend is payable April 30, 2026, to shareholders of record as of April 3, 2026. Please contact investors@morningstar.com with any questions.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRSP","MORN","LU1861558580.USD","LU1878469433.USD","BK4598","BK4588","LU1861559042.SGD","BK4112","BK4585","BK4556","LU2065731478.USD","BK4611"],"gpt_icon":0},{"id":"2619597111","title":"Cathie Wood Invests Over $10M in CRISPR and PAYP Stocks, Trims Stakes in TER and IONS","url":"https://stock-news.laohu8.com/highlight/detail?id=2619597111","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619597111?lang=en_us&edition=fundamental","pubTime":"2026-03-13 10:12","pubTimestamp":1773367952,"startTime":"0","endTime":"0","summary":"Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made several notable portfolio moves on Thursday, March 12, according to the firm’s daily tra...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/cathie-wood-invests-over-10m-in-crispr-and-payp-stocks-trims-stakes-in-ter-and-ions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/cathie-wood-invests-over-10m-in-crispr-and-payp-stocks-trims-stakes-in-ter-and-ions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1861559042.SGD","LU0957808578.USD","BK4147","IE00BN0W2V16.EUR","IONS","ARKK","TERG","ARKW","BK4611","LU0444971666.USD","LU1861558580.USD","BK4543","IE00BN0W2T93.GBP","BK4548","BK4588","ARKQ","BK4585","IE00BN0W2W23.USD","CRSP","BK4139","ARKX","BK4544","BK4556","TER","LU1642822529.SGD","LU1815336760.USD","PAYP","ARKF","ARKG"],"gpt_icon":0},{"id":"2618594070","title":"CRSP, SOLQ: Cathie Wood’s ARK ‘Buys the Dip’ in CRISPR and Solana Staking ETF","url":"https://stock-news.laohu8.com/highlight/detail?id=2618594070","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618594070?lang=en_us&edition=fundamental","pubTime":"2026-03-11 21:10","pubTimestamp":1773234600,"startTime":"0","endTime":"0","summary":"Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made targeted buys in biotech and cryptocurrency sectors on Tuesday, March 10, capitalizing o...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/crsp-solq-cathie-woods-ark-buys-the-dip-in-crispr-and-solana-staking-etf?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/crsp-solq-cathie-woods-ark-buys-the-dip-in-crispr-and-solana-staking-etf?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARKK","ARKQ","BK4588","FDN","CRSP","ARKX","ARKG","LU1861558580.USD","SOLT","BK4585","BK4544","BK4611","BK4139","BK4550","LU1861559042.SGD","BK4556"],"gpt_icon":0},{"id":"2618094132","title":"Crispr Therapeutics prices upsized convertible senior notes offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2618094132","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618094132?lang=en_us&edition=fundamental","pubTime":"2026-03-11 19:16","pubTimestamp":1773227780,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics (CRSP) announced the pricing of $550M aggregate principal amount of its convertible senior notes due 2031 in a private offering...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-prices-upsized-convertible-senior-notes-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-prices-upsized-convertible-senior-notes-offering-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4556","BK4139","BK4611","LU1861559042.SGD","BK4539","CRSP","BK4585","LU1861558580.USD","BK4588","LENZ"],"gpt_icon":0},{"id":"2618404913","title":"Regulatory Disruptions at FDA Threaten Editas Medicine’s Gene-Editing Timelines and Commercial Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2618404913","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618404913?lang=en_us&edition=fundamental","pubTime":"2026-03-11 14:02","pubTimestamp":1773208935,"startTime":"0","endTime":"0","summary":"Editas Medicine Inc. (EDIT) has disclosed a new risk, in the Regulation category. Disruptions at the FDA and other government agencies could materi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/regulatory-disruptions-at-fda-threaten-editas-medicines-gene-editing-timelines-and-commercial-prospects?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/regulatory-disruptions-at-fda-threaten-editas-medicines-gene-editing-timelines-and-commercial-prospects?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4556","BK4139","BK4588","EDIT","LABU"],"gpt_icon":0},{"id":"2618996935","title":"Cathie Wood’s ARK Investment buys 281K shares of Crispr Therapeutics today","url":"https://stock-news.laohu8.com/highlight/detail?id=2618996935","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618996935?lang=en_us&edition=fundamental","pubTime":"2026-03-11 09:05","pubTimestamp":1773191109,"startTime":"0","endTime":"0","summary":"21:03 EDT Cathie Wood’s ARK Investment buys 281K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ultimate source for rea...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-281k-shares-of-crispr-therapeutics-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cathie-woods-ark-investment-buys-281k-shares-of-crispr-therapeutics-today-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ARKK","BK4544","BK4539","BK4556","BK4611","ARKG","LENZ","LU1861559042.SGD","BK4588","ARKQ","BK4007","BK4139","ARKX","CRSP","BK4585","LU1861558580.USD"],"gpt_icon":0},{"id":"2618574049","title":"What's Going On With CRISPR Therapeutics Stock Today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2618574049","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618574049?lang=en_us&edition=fundamental","pubTime":"2026-03-11 00:56","pubTimestamp":1773161760,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics fell Tuesday after unveiling a $350 million convertible notes offering, overshadowing recent momentum from Casgevy uptake and fourth-quarter revenue growth.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/10/Crispr-Therapeutics.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/10/Crispr-Therapeutics.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/26/03/51166078/whats-going-on-with-crispr-therapeutics-stock-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/03/51166078/whats-going-on-with-crispr-therapeutics-stock-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4611","CRSP","BK4585","LU1861558580.USD","BK4588","LU1861559042.SGD","BK4556","BK4139"],"gpt_icon":0},{"id":"2618952795","title":"Crispr Therapeutics falls -9.2%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618952795","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618952795?lang=en_us&edition=fundamental","pubTime":"2026-03-11 00:05","pubTimestamp":1773158715,"startTime":"0","endTime":"0","summary":"Crispr Therapeutics (CRSP) is down -9.2%, or -$5.38 to $53.40. Published first on TheFly – the ultimate source for real-time, market-moving breakin...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-falls-9-2-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/crispr-therapeutics-falls-9-2-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4611","LENZ","CRSP","BK4585","BK4556","BK4588","LU1861559042.SGD","LU1861558580.USD","BK4139","BK4007"],"gpt_icon":0},{"id":"2618516379","title":"Crispr Therapeutics Falls on $350M Senior Note Private Placement","url":"https://stock-news.laohu8.com/highlight/detail?id=2618516379","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618516379?lang=en_us&edition=fundamental","pubTime":"2026-03-10 22:43","pubTimestamp":1773153780,"startTime":"0","endTime":"0","summary":"Shares of Crispr Therapeutics were lower after the company said it would raise $350 million through a private offering of senior notes.The stock was down 7.3% at $54.49 in Tuesday morning trading. The stock has gained 25% in the past year.The biopharmaceutical company, which focuses on gene-based medicines, said it plans to sell the convertible senior notes, due 2031, in a private offering to qualified institutional buyers. It said it will use the proceeds for general corporate purposes.Initial purchasers of the notes will have a 13-day option to buy an additional $52.5 million in senior notes, the company said.The notes will accrue interest payable on March 1 and Sept. 1 of each year, beginning Sept. 1 2026, and ending March 1, 2031. Notes can also be converted into common shares.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRSP","BK4539","BK4588","BK4139","BK4007","LENZ","LU1861559042.SGD","BK4556","BK4585","BK4611","LU1861558580.USD"],"gpt_icon":0},{"id":"2618342929","title":"CRISPR Therapeutics plans USD 350 million convertible senior notes offering due 2031","url":"https://stock-news.laohu8.com/highlight/detail?id=2618342929","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618342929?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:09","pubTimestamp":1773140981,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics said it plans a private offering of USD 350 million of convertible senior notes due 2031. The company expects to give initial purchasers an option to buy up to an additional USD 52.5 million of notes, bringing the potential total to USD 402.5 million. The notes are senior unsecured obligations, with interest payable semiannually starting Sept. 1, 2026. Proceeds are expected to be used for general corporate purposes.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL3sbqch:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","LU2095319765.USD","LU0314104364.USD","BK4588","CRSP","LU1861558580.USD","SG9999014005.SGD","BK4139","SG9999014021.USD","BK4112","IE00B3QW5Z07.USD","SG9999014039.USD","BK4556","LU1861559042.SGD","LU2210150020.SGD","LU2210149790.SGD","IE00BGHQF748.EUR","NDAQ","BK4585","BK4611","SG9999014013.SGD","IE00B64PRP62.GBP"],"gpt_icon":0},{"id":"2618934225","title":"CRISPR Therapeutics Announces Proposed Convertible Senior Notes Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2618934225","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618934225?lang=en_us&edition=fundamental","pubTime":"2026-03-10 19:00","pubTimestamp":1773140400,"startTime":"0","endTime":"0","summary":"ZUG, Switzerland and BOSTON, March  10, 2026  (GLOBE NEWSWIRE) -- CRISPR Therapeutics AG (Nasdaq: CRSP) (the “Company”) today announced its intention to offer, subject to market conditions and other f","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/10/3252625/0/en/CRISPR-Therapeutics-Announces-Proposed-Convertible-Senior-Notes-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","LU1861559042.SGD","BK4588","CRSP","LU1861558580.USD","BK4556","BK4585","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":32,"code":"91000000","status":"200"}]}}